Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
- PMID: 31403629
- PMCID: PMC11177630
- DOI: 10.3791/59973
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Abstract
The influenza virus remains a significant cause of mortality worldwide due to the limited effectiveness of currently available vaccines. A key challenge to the development of universal influenza vaccines is high antigenic diversity resulting from antigenic drift. Overcoming this challenge requires novel research tools to measure the breadth of serum antibodies directed against many virus strains across different antigenic subtypes. Here, we present a protocol for analyzing the breadth of serum antibodies against diverse influenza virus strains using a protein microarray of influenza antigens. This influenza antigen microarray is constructed by printing purified hemagglutinin and neuraminidase antigens onto a nitrocellulose-coated membrane using a microarray printer. Human sera are incubated on the microarray to bind antibodies against the influenza antigens. Quantum-dot-conjugated secondary antibodies are used to simultaneously detect IgG and IgA antibodies binding to each antigen on the microarray. Quantitative antibody binding is measured as fluorescence intensity using a portable imager. Representative results are shown to demonstrate assay reproducibility in measuring subtype-specific and cross-reactive influenza antibodies in human sera. Compared to traditional methods such as ELISA, the influenza antigen microarray provides a high throughput multiplexed approach capable of testing hundreds of sera for multiple antibody isotypes against hundreds of antigens in a short time frame, and thus has applications in sero-surveillance and vaccine development. A limitation is the inability to distinguish binding antibodies from neutralizing antibodies.
Figures





Similar articles
-
Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies.mSphere. 2018 Dec 12;3(6):e00592-18. doi: 10.1128/mSphere.00592-18. mSphere. 2018. PMID: 30541779 Free PMC article.
-
Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model.mBio. 2017 Sep 19;8(5):e01463-17. doi: 10.1128/mBio.01463-17. mBio. 2017. PMID: 28928215 Free PMC article.
-
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.J Virol. 2018 Aug 16;92(17):e01006-18. doi: 10.1128/JVI.01006-18. Print 2018 Sep 1. J Virol. 2018. PMID: 29925654 Free PMC article.
-
Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.Front Immunol. 2021 Nov 16;12:786617. doi: 10.3389/fimmu.2021.786617. eCollection 2021. Front Immunol. 2021. PMID: 34868073 Free PMC article. Review.
-
Influenza Hemagglutinin Structures and Antibody Recognition.Cold Spring Harb Perspect Med. 2020 Aug 3;10(8):a038778. doi: 10.1101/cshperspect.a038778. Cold Spring Harb Perspect Med. 2020. PMID: 31871236 Free PMC article. Review.
Cited by
-
Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score.mSphere. 2021 Apr 28;6(2):e00203-21. doi: 10.1128/mSphere.00203-21. mSphere. 2021. PMID: 33910993 Free PMC article.
-
Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components.Front Immunol. 2021 Jul 14;12:692151. doi: 10.3389/fimmu.2021.692151. eCollection 2021. Front Immunol. 2021. PMID: 34335601 Free PMC article.
-
Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.Transfusion. 2022 Oct;62(10):1997-2011. doi: 10.1111/trf.17083. Epub 2022 Sep 5. Transfusion. 2022. PMID: 36054476 Free PMC article.
-
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.NPJ Vaccines. 2021 Nov 4;6(1):132. doi: 10.1038/s41541-021-00396-3. NPJ Vaccines. 2021. PMID: 34737318 Free PMC article.
-
A modular microarray imaging system for highly specific COVID-19 antibody testing.Lab Chip. 2020 Sep 21;20(18):3302-3309. doi: 10.1039/d0lc00547a. Epub 2020 Aug 3. Lab Chip. 2020. PMID: 32743622 Free PMC article.
References
-
- Murray CJ et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380 (9859), 2197–2223 (2012). - PubMed
-
- Renegar KB, Crouse D, Floyd RA, Krueger J. Progression of influenza viral infection through the murine respiratory tract: the protective role of sleep deprivation. Sleep. 23 (7), 859–863 (2000). - PubMed
-
- Fauci AS Seasonal and pandemic influenza preparedness: science and countermeasures. Journal of Infectious Diseases. 194 Suppl 2, S73–76 (2006). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous